



European
Commission

Personalised Medicine Conference 2016

Challenge 5 Shaping Sustainable Healthcare


1-2 June 2016, Brussels

Geatano Guglielmi MD, PhD

Research and
Innovation



Circle of the five Challenges





Challenge Group 5

Personalised Medicine and Healthcare System Preliminary Considerations

- Personalised Medicine is the new revolution in medicine
- Today PM is **dramatically changing the traditional paradigm in medicine with huge consequences** for health care systems, similar to the antibiotics revolution in 20th century
- PM is a major breakthrough in delivering high-quality care and reducing adverse events, yet there are uncertain effects on healthcare budgets
- Health policy and economic research can be the first resource to help us use PM therapies in a sustainable manner in healthcare systems



CH5 Planned roadmap activity clusters

- **RESEARCH COLLABORATION BETWEEN INDUSTRY, ACADEMIA, HEALTHCARES PROVIDERS AND PATIENTS**
 - ✓ Only a great collaboration in PM Research can permit to reduce the actual PM costs and offer our citizens the best therapies without risk for the sustainability of healthcare systems
 - ✓ Collaborative research can help Policy Makers to identify better the specific PM R&D initiatives to support
- **ECONOMIC RESEARCH**
 - ✓ Economic research is an important instrument to ensure a real benefit for all citizens, and avoid that PM therapies are available only for the rich



CH5 Planned roadmap activity clusters

• ETHICAL RESEARCH

- The PM impact on “Omics” Data request to stress the ethical research aspects to avoid an improper use
- Individual wellbeing connected to PM therapies is strictly linked to a correct use of the personal data

• NHS MANAGEMENT RESEARCH AND SOCIAL COLLABORATION

- The opportunity offered by PM requires to change many aspects in NHS organisation
- Health Professionals in NHS need to take into consideration PM opportunity and ethical aspects
- Collaborations between patients and social institutions can offer additional value to PM research for positive research impacts



Some points for the Panel Discussion

- ✓ ***Learning from initial experiences of implementing PM in healthcare systems***
- ✓ ***Health economic research***
- ✓ ***PM and changing strategies in healthcare decision policies***
- ✓ ***Other relevant aspects for the healthcare system***



Plenary talks of Challenge Group 5: The Keynotes

***A framework on impact of PM in
National Health Systems***

Walter Ricciardi, President, Istituto
Superiore di Sanita, Rome - Italy

***Experience of implementing
personalised medicine approaches in
EU countries***

Frédérique Nowak, Institut national du
cancer (INCa), Paris - France

Andres Metspalu, Director, Estonian
Genome Center at the University of
Tartu



Plenary talks of Challenge Group 5: The Panel

Moderator:

Mary Harney, former Irish Health Minister and Deputy Prime Minister

Round table discussion

Health economic research

Maarten J. IJzerman, Professor, University of Twente, Enschede

Opportunity for collaborative research and collaboration between academia and industry and health providers for sustainability

Varda Shalev, Director, Institute for Health Research and Innovation, Maccabi Health Systems, Tel Aviv

Health system management research and social collaboration

Maria Aguirre Rueda, Director for Health Research and Innovation, Basque Government

Roberto Salgado, GasthuisZusters Antwerpen Hospitals, Institut Jules Bordet, Brussels

Matthias Perleth, Gemeinsamer Bundesausschuss, Berlin

Final remarks:

Walter Ricciardi, President, Istituto Superiore di Sanità, Rome

